Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19)

Clin Infect Dis. 2021 Dec 6;73(11):e4020-e4024. doi: 10.1093/cid/ciaa1637.

Abstract

We provide detailed clinical, virological, and immunological data of a B-cell-depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.

Keywords: COVID-19; convalescent plasma; follicular lymphoma; obinutuzumab; remdesivir.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Alanine / analogs & derivatives
  • COVID-19 Drug Treatment*
  • COVID-19 Serotherapy
  • COVID-19* / therapy
  • Humans
  • Immunization, Passive
  • SARS-CoV-2

Substances

  • remdesivir
  • Adenosine Monophosphate
  • Alanine